Chronic kidney disease (CKD)

#Chronic kidney disease (CKD) #Clinical trial #Japan

Asahi Kasei Pharma advances refractory disease drug to trial 

Asahi Kasei Pharma has advanced its treatment for refractory diseases to Phase I clinical trial.  AK1960, a novel Endothelin A (ETA) receptor antagonist, has been developed in collaboration with drug discovery company Alchemedicine, which entered a license agreement with Asahi Kasei Pharma in 2022.  In preclinical… Read More

#News

Kidneys
#AstraZeneca #Chronic kidney disease (CKD) #Kidney disease #National Institute for Health and Care Excellence (NICE)

More patients to become eligible for chronic kidney disease treatment 

The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases. This is the case if: It is an add-on to optimised standard care including the highest… Read More

#News

Heart monitor
#Cardiovascular disease #Chronic kidney disease (CKD) #Diabetes #GLP-1 #Novo Nordisk #Weight loss

Oral semaglutide reduces risk of cardiovascular events

The results of the SOUL cardiovascular outcomes trial have demonstrated that Rybelsus (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).   The new data were featured during a late-breaking clinical… Read More

#News

Kidneys
#Boehringer Ingelheim #Chronic kidney disease (CKD) #Kidney disease #Phase III trial

Global trial to test combination for chronic kidney disease

A new multinational clinical trial will investigate whether a novel treatment can help slow the progression of chronic kidney disease (CKD). The EASi-KIDNEY trial will evaluate whether vicadrostat, also known as BI 690517, improves clinical outcomes when it is given in combination with existing treatments. Read More

#News

Dialysis machine
#Akebia #Chronic kidney disease (CKD) #FDA #Kidney disease

FDA approves new treatment option for anaemia due to kidney disease

The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) Tablets for the treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor… Read More

#News #Regulatory

Kidneys
#Chronic kidney disease (CKD) #Kidney disease #Rare disease #UK Kidney Association #University College London

Focus on rare disease treatments to beat kidney failure, says study

Focusing on rare conditions could significantly reduce the burden of kidney disease, according to a new study led by University College London (UCL) and the UK Kidney Association. The study, published in The Lancet to mark World Kidney Day on 14 March, draws on the largest… Read More

#News

#Chronic kidney disease (CKD) #Dermatology #MC2 Therapeutics #Phase II trial

Potential breakthrough in treatment of urea associated skin diseases

MC2 Therapeutics has completed enrolment in its Phase II MC2-25 Ph2 chronic kidney disease-associated pruritus trial, with topline results expected in Q2 2024. MC2-25 CKD is a first-in-class drug candidate and could represent a potential breakthrough in the understanding and treatment of urea associated skin diseases. Read More

#News

Kidneys
#AstraZeneca #Cardiovascular disease #Chronic kidney disease (CKD) #Heart failure #Real world data

RWE shows risk of cutting RAASi medication in cardiorenal patients

A real-world evidence (RWE) study has shown the negative consequences of reducing or discontinuing renin-angiotensin-aldosterone system inhibitor (RAASi) medication in patients experiencing hyperkalaemia (HK). One analysis from AstraZeneca’s ZORA study showed that discontinuation of RAASi treatment following a HK episode in cardiorenal patients with chronic kidney… Read More

#News

Patient receiving dialysis treatment
#Chronic kidney disease (CKD) #FDA #GSK #Kidney disease

New oral option for anaemia of CKD approved in US

The US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the once-a-day treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.   Jesduvroq is the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) approved… Read More

#News #Regulatory

Patient checking own blood pressure
#Acquisition #AstraZeneca #Chronic kidney disease (CKD) #Hypertension #Mergers and acquisitions

AstraZeneca gains rights to novel aldosterone synthase inhibitor

AstraZeneca has entered into an agreement to acquire CinCor Pharma, a clinical-stage biopharmaceutical company, focused on developing treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.  As part of the deal, the company will acquire CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor… Read More

#Business & Investment #Editor's Choice #News

Dialysis machine
#Chronic kidney disease (CKD) #Scottish Medicines Consortium (SMC)

New treatment option for Scottish kidney transplant patients

The Scottish Medicines Consortium (SMC) has ruled Idefirix (imlifidase) clinically and cost-effective in highly sensitised adult patients prior to kidney transplant from a deceased donor.  The recommendation, which follows a positive ruling by the National Institute of Health and Care Excellence (NICE), marks an important milestone as highly sensitised… Read More

#News #Regulatory

#AstraZeneca #Chronic kidney disease (CKD)

Kidney disease has considerable public impact, study says  

The burden of chronic kidney disease (CKD) in adult populations has found to be greater than previously estimated, according to the latest real-world evidence study.  Results from the CArdioREnal and MEtabolic (CaReMe) CKD study which was sponsored by AstraZeneca found that around 10% of the adult population… Read More

#News